"Acetylcysteine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.
| Descriptor ID |
D000111
|
| MeSH Number(s) |
D02.886.030.230.259 D12.125.166.230.259
|
| Concept/Terms |
Acetylcysteine- Acetylcysteine
- N-Acetyl-L-cysteine
- N Acetyl L cysteine
- N-Acetylcysteine
- N Acetylcysteine
- Mercapturic Acid
- Acid, Mercapturic
Acetylcysteine Sodium- Acetylcysteine Sodium
- Sodium, Acetylcysteine
- Acetylcysteine, Monosodium Salt
- Monosodium Salt Acetylcysteine
Fluprowit- Fluprowit
- Optipect Hustengetränk
- Hustengetränk, Optipect
- Muco Sanigen
- Sanigen, Muco
|
Below are MeSH descriptors whose meaning is more general than "Acetylcysteine".
Below are MeSH descriptors whose meaning is more specific than "Acetylcysteine".
This graph shows the total number of publications written about "Acetylcysteine" by people in this website by year, and whether "Acetylcysteine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 7 | 5 | 12 |
| 2018 | 12 | 9 | 21 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Acetylcysteine" by people in Profiles.
-
N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect. 2022 01; 84(1):94-118.
-
N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. Infect Dis (Lond). 2021 11; 53(11):847-854.
-
A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. 2021 Dec; 73(6):1650-1659.
-
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. FASEB J. 2021 06; 35(6):e21651.
-
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021 06 01; 72(11):e736-e741.
-
The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 12; 22(1):271.
-
N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. Antioxid Redox Signal. 2021 11 10; 35(14):1207-1225.
-
Antioxidants other than vitamin C may be detected by glucose meters: Immediate relevance for patients with disorders targeted by antioxidant therapies. Clin Biochem. 2021 Jun; 92:71-76.
-
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients]. Vopr Virusol. 2021 03 07; 66(1):40-46.
-
The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021 03 06; 13(3).